• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

10.42 +0.46 (+4.62%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,987,428
Open 10.43
Bid (Size) 9.500 (200)
Ask (Size) 10.67 (100)
Prev. Close 9.960
Today's Range 9.990 - 10.66
52wk Range 3.895 - 14.93
Shares Outstanding 54,532,614
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
February 05, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire

Performance

YTD
+27.5%
+27.5%
1 Month
+23.3%
+23.3%
3 Month
-16.4%
-16.4%
6 Month
+13.3%
+13.3%
1 Year
-14.9%
-14.9%

More News

Read More
News headline image
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
January 12, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
December 04, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
December 03, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
December 01, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
November 24, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
November 20, 2025
Via Benzinga
News headline image
This Bellring Brands Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
November 20, 2025
Via Benzinga
News headline image
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
November 20, 2025
Via Benzinga
News headline image
Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday ↗
November 14, 2025
Via Benzinga
News headline image
ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates
November 13, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety
November 13, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 07, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor
November 06, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
November 04, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
October 27, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 05, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
August 27, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer
August 18, 2025
From ORIC Pharmaceuticals
Via GlobeNewswire
News headline image
ORIC Pharmaceuticals Inc (NASDAQ:ORIC) Reports Q2 2025 Wider Loss but Extends Cash Runway with Strategic Restructuring ↗
August 12, 2025
Via Chartmill

Frequently Asked Questions

Is Oric Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Oric Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Oric Pharmaceuticals, Inc. - Common Stock trade on?
Oric Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock is ORIC on the Nasdaq Stock Market
What is the current price of Oric Pharmaceuticals, Inc. - Common Stock?
The current price of Oric Pharmaceuticals, Inc. - Common Stock is 10.42
When was Oric Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Oric Pharmaceuticals, Inc. - Common Stock was at 02/06/26 04:00 PM ET
What is the market capitalization of Oric Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Oric Pharmaceuticals, Inc. - Common Stock is 568.23M
How many shares of Oric Pharmaceuticals, Inc. - Common Stock are outstanding?
Oric Pharmaceuticals, Inc. - Common Stock has 568M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap